Beyond Platelet Inhibition: Potential Pleiotropic Effects of ADP-receptor Antagonists

Overview

Journal J Thromb Thrombolysis

Specialty Cardiology & Vascular Diseases

Date 2008 Apr 10

PMID 18398577

Citations 3

Authors

Srinivas Iyengar

Leroy E Rabbani

Affiliations

Soon will be listed here.

Abstract

The adenosine diphosphate (ADP) receptor antagonists, specifically the class of thienopyridines, have emerged as potent tools in the clinician's arsenal for the treatment of athero-thrombotic disease over the last two decades. Though these medications have been clearly demonstrated to have significant platelet-inhibiting effects, their potential positive impact on other systemic processes has been less well elucidated. Recent evidence points to a number of potential pleiotropic effects of these agents, most notably in the attenuation of several pro-inflammatory pathways, which may be independent of their anti-platelet-aggregating effect. Additionally, several new ADP receptor antagonists are under investigation; it remains to be seen if these agents possess any additional beneficial pleiotropic properties as well.

Citing Articles

Platelets, Protean Cells with All-Around Functions and Multifaceted Pharmacological Applications.

Puricelli C, Boggio E, Gigliotti C, Stoppa I, Sutti S, Giordano M Int J Mol Sci. 2023; 24(5).

PMID: 36901997 PMC: 10002540. DOI: 10.3390/ijms24054565.

N-(5-Ethylsulfanyl-1,3,4-thiadiazol-2-yl)-2-(4,5,6,7-tetrahydrothieno[3,2-c]pyri-din-5-yl)acetamide.

Zhi S, Mu S, Liu Y, Liu D Acta Crystallogr Sect E Struct Rep Online. 2011; 67(Pt 6):o1490.

PMID: 21754858 PMC: 3120429. DOI: 10.1107/S1600536811017107.

Secondary prevention strategies for coronary heart disease.

Weiner S, Rabbani L J Thromb Thrombolysis. 2009; 29(1):8-24.

PMID: 19693440 DOI: 10.1007/s11239-009-0381-8.

References

Bhatt D, Fox K, Hacke W, Berger P, Black H, Boden W . Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354(16):1706-17. DOI: 10.1056/NEJMoa060989. View

Cha J, Jeong M, Lee K, Bae H, Lim Y, Park K . Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. J Thromb Thrombolysis. 2003; 14(2):145-50. DOI: 10.1023/a:1023237029550. View

Liuzzo G, Biasucci L, Gallimore J, Grillo R, Rebuzzi A, Pepys M . The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994; 331(7):417-24. DOI: 10.1056/NEJM199408183310701. View

Cannon C, Husted S, Harrington R, Scirica B, Emanuelsson H, Peters G . Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the.... J Am Coll Cardiol. 2007; 50(19):1844-51. DOI: 10.1016/j.jacc.2007.07.053. View

Sabatine M, Cannon C, Gibson C, Lopez-Sendon J, Montalescot G, Theroux P . Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005; 352(12):1179-89. DOI: 10.1056/NEJMoa050522. View

Shackelford R, Alford P, Xue Y, Thai S, Adams D, Pizzo S . Aspirin inhibits tumor necrosis factoralpha gene expression in murine tissue macrophages. Mol Pharmacol. 1997; 52(3):421-9. DOI: 10.1124/mol.52.3.421. View

Frelinger 3rd A, Jakubowski J, Li Y, Barnard M, Fox M, Linden M . The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thromb Haemost. 2007; 98(1):192-200. View

Vivekananthan D, Bhatt D, Chew D, Zidar F, Chan A, Moliterno D . Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol. 2004; 94(3):358-60. DOI: 10.1016/j.amjcard.2004.04.035. View

Yusuf S, Zhao F, Mehta S, Chrolavicius S, Tognoni G, Fox K . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7):494-502. DOI: 10.1056/NEJMoa010746. View

10.

Molero L, Lopez-Farre A, Mateos-Caceres P, Fernandez-Sanchez R, Maestro M, Silva J . Effect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery. Br J Pharmacol. 2005; 146(3):419-24. PMC: 1576286. DOI: 10.1038/sj.bjp.0706340. View

11.

Aeberhard E, Henderson S, Arabolos N, Griscavage J, CASTRO F, Barrett C . Nonsteroidal anti-inflammatory drugs inhibit expression of the inducible nitric oxide synthase gene. Biochem Biophys Res Commun. 1995; 208(3):1053-9. DOI: 10.1006/bbrc.1995.1441. View

12.

Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, Ortak M . Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol. 2006; 26(7):1648-52. DOI: 10.1161/01.ATV.0000225288.74170.dc. View

13.

Gent M, Blakely J, Easton J, Ellis D, Hachinski V, Harbison J . The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989; 1(8649):1215-20. DOI: 10.1016/s0140-6736(89)92327-1. View

14.

Quinton T, Kim S, Dangelmaier C, Dorsam R, Jin J, Daniel J . Protein kinase C- and calcium-regulated pathways independently synergize with Gi pathways in agonist-induced fibrinogen receptor activation. Biochem J. 2002; 368(Pt 2):535-43. PMC: 1223015. DOI: 10.1042/BJ20020226. View

15.

Kwon G, Hill J, Corbett J, McDaniel M . Effects of aspirin on nitric oxide formation and de novo protein synthesis by RINm5F cells and rat islets. Mol Pharmacol. 1997; 52(3):398-405. DOI: 10.1124/mol.52.3.398. View

16.

Quinn M, Bhatt D, Zidar F, Vivekananthan D, Chew D, Ellis S . Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2004; 93(6):679-84. DOI: 10.1016/j.amjcard.2003.11.048. View

17.

Niitsu Y, Jakubowski J, Sugidachi A, Asai F . Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost. 2005; 31(2):184-94. DOI: 10.1055/s-2005-869524. View

18.

Azar R, Kassab R, Zoghbi A, Aboujaoude S, El-Osta H, Ghorra P . Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J. 2006; 151(2):521.e1-521.e4. DOI: 10.1016/j.ahj.2005.10.021. View

19.

Ridker P, Cushman M, Stampfer M, Tracy R, Hennekens C . Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336(14):973-9. DOI: 10.1056/NEJM199704033361401. View

20.

Storey R, Judge H, Wilcox R, Heptinstall S . Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost. 2002; 88(3):488-94. View